Lipids & metabolic liver disease
High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
Authors' conclusion
The prevalence of at-risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics.
Study context
- Population
- Individuals from outpatient primary care or endocrinology clinics, risk-stratified by NIS2+ (miR-34a-5p and YKL-40)
- Participants
- 798 individuals
- Exposure
- Obesity and T2D vs Without either condition vs At-risk MASH vs Low-risk vs Intermediate-risk
- Outcome
- Prevalence of at-risk MASH (MASH and significant fibrosis) by NIS2+ (score ≥ 0.68)
Main finding
As reported in the abstract
At-risk MASH by NIS2+
P < 0.001
Observational data: associations, not effects.
Further findings
Steatosis (CAP ≥ 288 dB/m): at-risk MASH vs low-risk
P < 0.001
Clinically significant fibrosis (VCTE ≥ 8.0 kPa): at-risk MASH vs low-risk
P < 0.001
AST or ALT ≥ 40 IU/L, hepatic insulin resistance (HOMA-IR) and adipose tissue insulin resistance (adipo-IR)
- More often in at-risk MASH than low-risk (all p < 0.001)
Correlation of NIS2+ with at-risk MASH by FAST
- R
- 0.67
- P
- P < 0.001
Correlation of NIS2+ with CK-18, ALT, AST and fibrosis by VCTE-LSM
- Correlated (all p < 0.001)
Original publication
High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics. Diabetes Obes Metab. Published 29 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →